Eckert & Ziegler BEBIG is a European-based group active in the medical device segment of the health care industry. Its core business is the production and distribution of medical products for the treatment of cancer using brachytherapy.
Brachytherapy is a form of radiotherapy that treats cancer by irradiation from a short distance. Two different forms of brachytherapy are used today: permanent and temporary brachytherapy. In permanent brachytherapy, a small radioactive source is implanted in the body, while in temporary brachytherapy, the radioactive source is placed directly inside or close to the site of the tumour for a limited and defined period.
Eckert & Ziegler BEBIG recently acquired the brachytherapy business of Biocompatibles Inc. as well as Mick Radio-Nuclear Instruments, Inc..
Eckert & Ziegler BEBIG offers a complete portfolio of brachytherapy products, which comprises the HDR afterloader, MultiSource®, the permanent prostate implants so called seeds in a loose (IsoSeed®) and stranded form (IsoCord®), as well as ophthalmic applicators for the treatment of eye tumours. Eckert & Ziegler BEBIG is also the only provider worldwide of the miniaturised cobalt Co-60 source used in the HDR afterloading systems.
The company’s products and equipment are intended for use by oncologists, radiotherapists, urologists, ophthalmologists and medical physicists.
Ophthalmic Oncology Group (OOG) Spring Meeting 2014
07.03 - 09.03.2014, Krakow, Poland